Graybug Vision, Inc. (GRAY) Stock

About Graybug Vision, Inc.

Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.

Graybug Vision, Inc. is headquartered in US.

Graybug Vision, Inc. (GRAY) stock trades at $5.50 with a market capitalization of $120.98M. The stock is valued at a price-to-earnings (P/E) ratio of -4.23, price-to-book of -74.78, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.88 and $20.30, and currently trades 72.9% below its 52-week high.

On profitability, Graybug Vision, Inc. generates a return on equity (ROE) of 428.57% — well above the market average, a sign of a high-quality business, return on capital employed of -674.61%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.graybug.vision